Free Trial Information
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

...ground for Santhera, which was created in 2004 through the merger of MyoContract AG and Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 9, 2006
Company News

Santhera Pharmaceuticals AG supply/service news

...will receive undisclosed revenues from the newco. Santhera was formed through the 2004 merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 9, 2006
Strategy

Working through the checklist

...more focus as well. Santhera (Liestal, Switzerland) was created in 2004 through the merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...once-per-day dosing." Santhera Pharmaceuticals AG (Liestal, Switzerland), which was formed through the 2004 merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 24, 2005
Emerging Company Profile

Mutabilis: Blocking the blood highway

...one of the natural substrates to the undisclosed enzyme it's targeting. Mutabilis then worked with Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 24, 2005
Emerging Company Profile

Corporate Profile

...Nassif University collaborators: University of Medicine Necker, Ecole Normale Superiore Corporate partners: 4SC AG , Graffinity Pharmaceuticals AG...
Read More
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...a company-driven deal. Another recently completed company-driven merger was between functional genomics and metabolic company Graffinity Pharmaceuticals AG...
Read More
BioCentury | Sep 13, 2004
Company News

Graffinity Pharmaceuticals AG, MyoContract deal

...becomes CEO of Santhera, and Thomas Meier, founder and CEO of MyoContract, is now CSO. Graffinity Pharmaceuticals AG...
Read More
BioCentury | Dec 8, 2003
Company News

Graffinity Pharmaceuticals AG management update

Graffinity Pharmaceuticals AG , Heidelberg, Germany Business: Functional genomics Hired: Paul Edwards as associate director of medicinal chemistry, formerly principle scientist at Pfizer Global Research and Development WIR Staff...
Read More
BioCentury | Nov 17, 2003
Company News

Graffinity Pharmaceuticals AG management update

Graffinity Pharmaceuticals AG , Heidelberg, Germany Business: Functional genomics Hired: Mathias Woker as VP of business development USA, formerly VP of business development at Spherics Inc. WIR Staff...
Read More
Items per page:
1 - 10 of 19
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

...ground for Santhera, which was created in 2004 through the merger of MyoContract AG and Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 9, 2006
Company News

Santhera Pharmaceuticals AG supply/service news

...will receive undisclosed revenues from the newco. Santhera was formed through the 2004 merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 9, 2006
Strategy

Working through the checklist

...more focus as well. Santhera (Liestal, Switzerland) was created in 2004 through the merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...once-per-day dosing." Santhera Pharmaceuticals AG (Liestal, Switzerland), which was formed through the 2004 merger of Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 24, 2005
Emerging Company Profile

Mutabilis: Blocking the blood highway

...one of the natural substrates to the undisclosed enzyme it's targeting. Mutabilis then worked with Graffinity Pharmaceuticals AG...
Read More
BioCentury | Jan 24, 2005
Emerging Company Profile

Corporate Profile

...Nassif University collaborators: University of Medicine Necker, Ecole Normale Superiore Corporate partners: 4SC AG , Graffinity Pharmaceuticals AG...
Read More
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...a company-driven deal. Another recently completed company-driven merger was between functional genomics and metabolic company Graffinity Pharmaceuticals AG...
Read More
BioCentury | Sep 13, 2004
Company News

Graffinity Pharmaceuticals AG, MyoContract deal

...becomes CEO of Santhera, and Thomas Meier, founder and CEO of MyoContract, is now CSO. Graffinity Pharmaceuticals AG...
Read More
BioCentury | Dec 8, 2003
Company News

Graffinity Pharmaceuticals AG management update

Graffinity Pharmaceuticals AG , Heidelberg, Germany Business: Functional genomics Hired: Paul Edwards as associate director of medicinal chemistry, formerly principle scientist at Pfizer Global Research and Development WIR Staff...
Read More
BioCentury | Nov 17, 2003
Company News

Graffinity Pharmaceuticals AG management update

Graffinity Pharmaceuticals AG , Heidelberg, Germany Business: Functional genomics Hired: Mathias Woker as VP of business development USA, formerly VP of business development at Spherics Inc. WIR Staff...
Read More
Items per page:
1 - 10 of 19